Navigation Links
Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial
Date:5/21/2009

1,000 deaths in the EU each year.(7) Coronary artery disease occurs when the arteries become narrowed or clogged by cholesterol and fat deposits and cannot supply enough blood to the heart. In some cases, a blood clot may partially or totally block the blood supply to the heart, resulting in ACS.(8) Many ACS patients are managed with PCI, which usually includes a stent placement.

About Prasugrel

Daiichi Sankyo Company, Limited (TSE: 4568) and Eli Lilly and Company (NYSE: LLY) are co-developing prasugrel, an investigational oral antiplatelet agent invented by Daiichi Sankyo and its Japanese research partner Ube Industries, Ltd., as a potential treatment, initially for patients with acute coronary syndrome undergoing PCI. Prasugrel works by inhibiting platelet activation and subsequent aggregation by blocking the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface. Antiplatelet agents prevent platelets from clumping or sticking together, which can result in clogged arteries and may lead to heart attack or stroke.

About Daiichi Sankyo

A global pharmaceutical innovator, Daiichi Sankyo Company, Ltd., was established in 2005 through the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. Areas of central focus for Daiichi Sankyo research and development are thrombotic disorders, malignant neoplasm, diabetes mellitus, and autoimmune disorders. Equally important to the company are hypertension, hyperlipidemia or atherosclerosis and bacterial infections. For more information, visit www.daiichisankyo.com.

Daiichi Sankyo, Inc., headquartered in Par
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting
2. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
3. Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models
4. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
5. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis
6. Intrinsic Bioprobes, Inc. Enters into a $1.27M Contract with the National Cancer Institute to Develop Multiplex Mass Spectrometric Immunoassays for Detection of Low Abundance Cancer-Related Proteins
7. First Multiple Dose Clinical Trial of TorreyPines Therapeutics Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
8. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
9. International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia"
10. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
11. EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 2014 Leatherwood Plastics has selected ... to stay competitive in the semiconductor, clean room ... ultimately impact product quality and productivity, according to ... Established in 1980 in Lewisville, TX, Leatherwood ... have left the business. Much of Leatherwood’s equipment ...
(Date:9/18/2014)... DIEGO , Sept. 18, 2014  MEI Pharma, Inc. ... the clinical development of novel therapies for cancer, announced today ... Executive Officer, will present at BioCentury,s NewsMakers in the ... 8:30 a.m. Eastern time from the Millennium Broadway Hotel & ... live webcast of the presentation can be accessed at ...
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire/ - Oncothyreon Inc. ... of previously announced concurrent but separate underwritten offerings of ... to the public of $2.00 per share, for expected ... its Series A Convertible Preferred Stock at a price ... gross proceeds of $20 million. Each share of Series ...
(Date:9/18/2014)... 2014   Sigma-Aldrich Corporation (Nasdaq: ... into a new gene editing partnership with the ... Under the partnership, Sigma-Aldrich will provide the Vector ... and dedicated gene editing bioinformaticians. The ... at the U-M Medical School. One initiative already ...
Breaking Biology Technology:Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4
... SAN DIEGO, April 28, 2011 Optimer Pharmaceuticals, Inc. ... from the DIFICID™ Phase 3 trials will be presented ... Place, Chicago, ILMay 7-10, 2011 Poster Presentation Information: Title: ... Treatment of Clostridium difficile Infection: ...
... Calif., April 28, 2011 AquaStar Holdings, Inc. (Pink ... that the United States Patent and Trademark Office has ... Sensor technology utilized by the Capwave Enzyme-Linked Immuno-Sorbent Assay ... Capillary Sensor" details research completed at the State University ...
... April 28, 2011 The Center for Business Intelligence (CBI), ... partnership with the Children,s Rare Disease Network and The Global ... coming up July 12 - 13, 2011 at the Doubletree ... about rare diseases. They affect few people individually, but there ...
Cached Biology Technology:Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings 2Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings 3AquaStar Holdings, Inc.'s Client Receives U.S. Patent 7,708,944 for Portable Capillary Sensor Technology 2CBI Announces Partnership With Children's Rare Disease Network and The Global Genes Project 2CBI Announces Partnership With Children's Rare Disease Network and The Global Genes Project 3
(Date:9/18/2014)... BUFFALO, N.Y. A sleep-promoting circuit located deep in ... deep sleep. Discovered by researchers at Harvard School of ... and Biomedical Sciences, this is only the second "sleep ... to be both necessary and sufficient to produce deep ... Neuroscience , the study demonstrates that fully half of ...
(Date:9/18/2014)... Worcester, Mass. A novel robotic system that can ... currently being tested as part of a biomedical research ... with the aim of determining if the robot, in ... biopsies faster, more accurate, less costly, and less discomforting ... potential to deliver prostate cancer therapies with greater precision. ...
(Date:9/18/2014)... No matter how many times it,s demonstrated, it,s ... creatures. , But by using a signaling ... alter their behavior to suit their population. In ... are present, and act accordingly. , Once the ... may change from innocuous to pathogenic, or from ...
Breaking Biology News(10 mins):No sedative necessary: Scientists discover new 'sleep node' in the brain 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3
... movements during the Vietnam war could help ecologists monitor ... in the British Ecological Society's Journal of Applied Ecology. ... recorded the vibrations from the footfalls of elephants and ... a geophone buried near a path leading to a ...
... discovered that a protein prolonging life in mice works by ... several species. In mice, the researchers discovered, it acts as ... , Therapies based on this hormone could prove to be ... Dr. Makoto Kuro-o, assistant professor of pathology and senior author ...
... Coyotes tend to avoid human contact. But recently, coyotes ... States, including southeastern New York state, attacking neighborhood pets ... "This kind of aggressive behavior is usually the last ... as small children that are perceived by the coyotes ...
Cached Biology News:Vietnam war technology could aid elephant conservation 2Scientists find that protein controls aging by controlling insulin 2Why are coyotes getting more aggressive? 2
...
TXNL2 Antibody...
Mouse monoclonal [CIG 3A11/5] to Cig2 (rating: *****) ( Abpromise for all tested applications)....
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Biology Products: